Abstract
Chimerism is an unusual state in which a person’s body comprises cells from genetically different people. Chimerism testing allows monitoring for the relative proportion of recipient and donor-derived cell subsets in recipient blood and bone marrow. In the bone marrow transplant setting, chimerism testing is the standard diagnostic tool for early detection of graft rejection and the risk of malignant disease relapse. Chimerism testing enables the identification of patients with increased risk for recurrence of the underlying disease. Herein, we describe a step-by-step technical procedure of a novel, commercially available, next-generation sequencing-based chimerism testing method for use in the clinical laboratory.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Jacque N, Nguyen S, Golmard JL, Uzunov M, Garnier A, Leblond V, Vernant JP, Bories D, Dhedin N (2015) Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemia. Bone Marrow Transplant 50(2):259–265. https://doi.org/10.1038/bmt.2014.254
Baron F, Sandmaier BM (2006) Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 20(10):1690–1700. https://doi.org/10.1038/sj.leu.2404335
Talwar S, Khan F, Nityanand S, Agrawal S (2007) Chimerism monitoring following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 39(9):529–535. https://doi.org/10.1038/sj.bmt.1705626
Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T (2005) How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 35(2):107–119. https://doi.org/10.1038/sj.bmt.1704715
Matthes-Martin S, Lion T, Haas OA, Frommlet F, Daxberger H, Konig M, Printz D, Scharner D, Eichstill C, Peters C, Lawitschka A, Gadner H, Fritsch G (2003) Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 17(10):1934–1942. https://doi.org/10.1038/sj.leu.2403087
Miura Y, Tanaka J, Toubai T, Tsutsumi Y, Kato N, Hirate D, Kaji M, Sugita J, Shigematsu A, Iwao N, Ota S, Masauzi N, Fukuhara T, Kasai M, Asaka M, Imamura M (2006) Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation. Bone Marrow Transplant 37(9):837–843. https://doi.org/10.1038/sj.bmt.1705352
Zeiser R, Spyridonidis A, Wasch R, Ihorst G, Grullich C, Bertz H, Finke J (2005) Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia 19(5):814–821. https://doi.org/10.1038/sj.leu.2403719
Bader P, Stoll K, Huber S, Geiselhart A, Handgretinger R, Niemeyer C, Einsele H, Schlegel PG, Niethammer D, Beck J, Klingebiel T (2000) Characterization of lineage-specific chimerism in patients with acute leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse. Br J Haematol 108(4):761–768. https://doi.org/10.1046/j.1365-2141.2000.01927.x
Frankel W, Chan A, Corringham RE, Shepherd S, Rearden A, Wang-Rodriguez J (1996) Detection of chimerism and early engraftment after allogeneic peripheral blood stem cell or bone marrow transplantation by short tandem repeats. Am J Hematol 52(4):281–287. https://doi.org/10.1002/(SICI)1096-8652(199608)52:4<281::AID-AJH7>3.0.CO;2-O
Buno I, Nava P, Simon A, Gonzalez-Rivera M, Jimenez JL, Balsalobre P, Serrano D, Carrion R, Gomez-Pineda A, Diez-Martin JL (2005) A comparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation. Haematologica 90(10):1373–1379
Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C, Lamy T, Le Prise PY, Beauplet A, Bories D, Semana G, Quelvennec E (2002) Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 99(12):4618–4625. https://doi.org/10.1182/blood.v99.12.4618
Jimenez-Velasco A, Barrios M, Roman-Gomez J, Navarro G, Buno I, Castillejo JA, Rodriguez AI, Garcia-Gemar G, Torres A, Heiniger AI (2005) Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms. Leukemia 19(3):336–343. https://doi.org/10.1038/sj.leu.2403622
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Wu, C., dela Cruz, T., Lai, J., Kong, D., Rajalingam, R. (2023). Immune Cell Lineage-Specific Chimerism Testing by Next-Generation Sequencing for Engraftment Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation. In: Myers, M.B., Schandl, C.A. (eds) Clinical Applications of Nucleic Acid Amplification. Methods in Molecular Biology, vol 2621. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2950-5_11
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2950-5_11
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2949-9
Online ISBN: 978-1-0716-2950-5
eBook Packages: Springer Protocols